| Revenue growth | 27% YoY in Q1FY27 |
|---|---|
| Margins | EBITDA Margin at 34.7%; PAT Margin improved to 25.6%. |
| Demand visibility | Strong customer engagement and increasing visibility on battery material off-take. |
| Management confidence | High; confident in sustainable long-term growth and expansion projects. |
Growth
Q1FY27 Revenue grew 27% YoY to ₹158.3 Cr; PAT rose 30% YoY to ₹40.6 Cr.
Outlook
Greenfield expansion and SAM Phase 1 on track for March 2027; total capacity targeted at 2,28,700 MT by FY30.
Risks
Challenging global environment, geopolitical uncertainties, supply chain disruptions, gas constraints, and elevated logistics costs.
Last quarter's promises, checked
Delivered
- Guided 25,000 MT Phase 1 SAM commissioning by April 2027 → On track for March 2027 (= BEAT)
- Guided 150-160 working capital days → delivered 154 days (= BEAT)
- Guided 10% revenue growth for Pharma/Food segment → delivered 10% (= BEAT)
Partly delivered
- Guided EBITDA margins returning to 37-38% → delivered 34.7% (= PARTIAL)
Investor Presentation filed with BSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,164.90
- Market cap
- ₹13,157 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.0×Sector 50.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported 27.9% YoY revenue growth in FY26 to ₹642.3cr, driven by specialty ingredients and international expansion. Management is pivoting towards high-value mineral molecules and a major entry into battery materials.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported record FY26 revenue of ₹642.3cr, driven by the listing, the NSS acquisition, and expansion into battery materials.
Sudeep Pharma Q4 FY26 Results: Net Profit ₹48.5 Cr, Up 9.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹182.3 Cr (+15.7% YoY) and net profit of ₹48.5 Cr (+9.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹48.5 Cr · +9.7% YoY